Sustained delivery of pan-VEGF inhibitor may reduce treatment burden in wet AMD
Click Here to Manage Email Alerts
NEW ORLEANS — Patients with wet age-related macular degeneration experienced a reduced treatment burden with sustained delivery sunitinib, according to a study presented here.
Veeral Sheth, MD, MBA, FACS, said GB-102 (sunitinib malate, Graybug Vision) is a pan-VEGF inhibitor.
“This is a platform that can be delivered with an intravitreal injection as a depot, which allows for sustained drug delivery,” he said at Retina Subspecialty Day at the American Academy of Ophthalmology meeting.
The phase 2b ALTISSIMO trial comprised 56 patients who had been diagnosed with wet AMD within 18 months and had at least three prior anti-VEGF injections, including one within the last 21 days. The study included GB-102 1 mg and 2 mg dosing groups that received treatment at day 1 and month 6, as well as a third group that received aflibercept 2 mg every 2 months. The GB-102 2 mg dosing group was discontinued after interim analysis.
In the GB-102 1 mg group, the median duration was 5 months in the core study and 12 months in the extension study, despite 61% of rescue treatments not meeting any rescue criteria or not experiencing an increase in central subfield thickness, Sheth said.
Before the study, patients in the GB-102 1 mg group had an average of 10.1 injections per year. After initiating treatment with GB-102, the average was 3.8 injections per year.
“That difference is even more stark when you look at patients in the extension study: 10.6 injections per year prior to enrollment and 2.8 injections per year on study,” Sheth said. “That’s a 73% reduction in treatment burden for these patients.”
Most adverse events were mild or moderate, and no cases of retinal vasculitis or retinal artery occlusion were reported.
Collapse
Sheth V, et al. Intravitreal sunitinib malate depot (GB-102): Durability and safety in wet age-related macular degeneration (ALTISSIMO, phase 2b). Presented at: American Academy of Ophthalmology meeting; Nov. 12-15, 2021; New Orleans.
Read more about
Click Here to Manage Email Alerts